Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
about
Critical appraisal of eculizumab for atypical hemolytic uremic syndromeEarly Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune DiseasesComplement therapy in atypical haemolytic uraemic syndrome (aHUS).Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case reportA Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic SyndromeA novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples.Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).Properdin in complement activation and tissue injury.NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways.Complement Activation Induces Neutrophil Adhesion and Neutrophil-Platelet Aggregate Formation on Vascular Endothelial Cells.
P2860
Q26750692-EE3A2A1C-6CA6-4BC6-BCF6-B18D10583413Q26766486-690A3A1C-89AB-4603-9B31-511D68B786DAQ33408733-7D3C6BB2-DAA6-4478-9694-DA10F6C36BC6Q33415471-283691AB-CAC7-4D2B-BECE-D7A3173DB890Q33416830-5CAE29B7-F198-4488-A7B5-47CDDFAF3744Q33417655-4256E987-8316-4325-B4DD-E2FCDC93B682Q33437634-CC59A29F-1EBA-4F68-82A5-C4BB7817E622Q33568131-A3A64BB3-9989-49A7-87C3-1925EF93EA5EQ33783126-35354DAA-5BAC-4343-A90D-05629684260CQ37200463-6DA41F05-020C-4B38-B978-73E72EA34A15Q38118454-63E9D35A-A5F2-4476-AADD-4B9B12B1D023Q40171437-0DA55EC2-0552-47E7-94C0-CAC55D872CFEQ45696232-E1779E45-57A7-43A6-8AE3-5DF3DDEA6C21
P2860
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@ast
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@en
type
label
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@ast
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@en
prefLabel
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@ast
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@en
P2093
P1433
P1476
Monitoring and modeling treatment of atypical hemolytic uremic syndrome.
@en
P2093
Christoph Licht
Susan E Quaggin
Viola F van Eimeren
P356
10.1016/J.MOLIMM.2012.10.044
P577
2012-12-03T00:00:00Z